A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible

Journal of Periodontology

Volumn 74, Issue 9, 2003, Pages 1348-1354

  Kaynak, Deniz ^a,e   Meffert, Roland ^b   Bostanci, Hamit ^a   Günhan, Ömer ^c   Özkaya, Özay Gököz ^d  

^a ANKARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

^e NONE   (Turkey)

Author keywords

Alendronate therapeutic use; Alveolar bone loss prevention and control; Bone resorption prevention and control; Osteoclasts; Periodontal disease drug therapy; Surgical flaps; Tissue factors

Indexed keywords

ALENDRONIC ACID; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; SODIUM CHLORIDE; THROMBOPLASTIN;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GRAFT; BONE STRUCTURE; CELL ACTIVITY; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; CRANIOFACIAL SURGERY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FIBROSIS; HISTOPATHOLOGY; INFLAMMATORY CELL; MALE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PERIODONTAL DISEASE; PERIODONTICS; PERIOSTEUM; POSTOPERATIVE COMPLICATION; RAT; TISSUE FLAP; TOOTH IMPLANTATION;

ALENDRONATE; ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; BONE RESORPTION; CHI-SQUARE DISTRIBUTION; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; INJECTIONS, SUBCUTANEOUS; MALE; MANDIBLE; MANDIBULAR DISEASES; OSTEOBLASTS; OSTEOCLASTS; PERIODONTIUM; RATS; SURGICAL FLAPS;

EID: 0242383367     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2003.74.9.1348     Document Type: Article

References (54)

1. Friedlaender G, Troiano N, Ishii M, Pelker R, Baron R. Abnormal bone remodeling; The consequences of therapeutic drugs and physical modalities. In: Brighton CT, Friedlaender G, Lane JM, eds. Bone Formation and Repair. Rosemont, IL: American Academy of Orthopedic Surgeons; 1994:289-297.
2. Canalis E, McCarthey, Centralla M. Growth factors and the regulation of bone remodeling. J Clin Invest 1988;81: 277-281.
3. Frost MH. Skeletal physiology and bone remodeling: An overview. In: Urist MR, ed. Fundamental and Clinical Bone Physiology. Philadelphia: J.B. Lippincott; 1980: 208-241.
4. Raisz LG, Rodan GA. Cellular basis for bone turnover. In: Avioli LV, Krane SM, eds. Metabolic Bone Disease and Clinically Related Disorders. Philadelphia: W.B. Saunders; 1990:1-41.
5. Yaffe A, Fine N, Binderman I. Regional accelerated phenomenon in the mandible following mucoperiosteal flap surgery. J Periodontol 1994;65:79-83.
6. Bragger U, Pasquali L, Kornman KS. Remodeling of interdental alveolar bone after periodontal flap procedure assessed by means of computer assisted densitometer image analysis (CADIA) for the assessment of alveolar bone density changes in furcations. J Clin Periodontol 1989;16:46-52.
7. Friedlaender GE, Troiano N, McKay J Jr., et al. Cyclosporin A induced changes in bone turnover. Trans Orthop Res Soc 1985;10:66.
8. Warren SB, Pelker RR, Friedlaender GE. Effects of short-term cyclosporin-A biomechanical properties of intact and fractured bone in the rat. J Orthop Res 1985;3: 96-100.
9. Allen HL, Wase A, Bear WT. Indomethacin and aspirin: Effect of non-steroidal anti-inflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand 1980;51:595-600.
10. Huo MH, Troiano NW, Petker RR, et al. The influence of ibuprofen on fracture repair: Biomechanical, biochemical, histologic and histomorphometric parameters in rats. Trans Orthop Res Soc 1990;15:168.
11. Fleish H. Bisphosphonates - History and experimental basis. Bone 1987;8:17-22.
12. Fleish H. Bisphosphonates-Pharmocology and use in the treatment of tumour induced hypercalcemic and metastatic bone disease. Drugs 1991;42:919-944.
13. Fleish H. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
14. Fask DK, Felix R, Dowse C, Newman WF, Fleish H. The effects of diphosphonates on the growth and glycolysis of connective tissue cells in culture. Biochem J 1978;172: 97-107.
15. Shinoda H, Adamek G, Felix R, Fleish H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
16. Carono A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-461.
17. Felix R, Graham R, Russell G, Fleish H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochem Biophys Acta 1976;429: 429-438.
18. Felix R, Bettex JD, Fleish H. Effect of diphosphonates on the synthesis of prostaglandins in calvaria cells. Calcif Tissue Int 1981;33:549-552.
19. Schenk R, Merz WA, Mühlbauer R, Russell RGG, Fleish H. Effect of ethane-1-hydroxy-1, 1-diphosphonate (EHDP) and dichloromethylene diphosphonate (C12MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973;11:196-214.
20. Miller SC, Jee WS. The comparative effects of dichloromethylene diphosphonate (CL2 MDP) and of ethane-1-hydroxy-1, 1-diphosphate (EHDP) on growth and remodeling of the rat tibia. Calcif Tissue Res 1977;23: 207-214.
21. Plasmans CM, Jap PH, Kuijpers W, Sloof TJ. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int 1980;32:247-256.
22. Fleish H. Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin Orthop Rel Res 1987;217:72-78.
23. Stone MD, Marshall DH, Hosking DJ, Perkins AC, Evans AJ, Wastie ML. Bisphosphonate space measurement in Paget's disease of bone treated with APD. J Bone Miner Res 1992;7:295-301.
24. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer related hypercalcemia. J Clin Oncol 1992;20:134-142.
25. Fleish H. The possible use of bisphosphonates in osteoporosis. In: Deluca HF, Mazess R, eds. Osteoporosis: Physiological Basis, Assessment and Treatment. Amsterdam: Elsevier; 1990:323-329.
26. Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleish H. The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res 1972;10: 302-313.
27. Fleish H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
28. Russell RG, Muhlbauer RC, Bisaz S, Williams DA, Fleish H. The influence of pyrophosphate, condensed phosphates, and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif Tissue Res 1970;6:183-196.
29. Gasser AB, Morgan DB, Fleish H, Richelle IJ. The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 1972;43:31-45.
30. Smith R, Russell RG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet 1971;1:945-947.
31. De Vries HR, Bijvoet OL. Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Neth J Med 1974;17:281-298.
32. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 1982;72: 221-226.
33. van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxy-propylidene)-1, 1-bisphosphonate (A.P.D). Lancet 1979; 1:803-805.
34. Minaire P, Berard E, Meunier PJ, Edovard C, Goedert G, Pilonchery G. Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J Clin Invest 1981;68:1086-1092.
35. Elomaa I, Blongvist C, Gröhn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983;1:146-149.
36. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 1995;333:1437-1443.
37. Kaynak D, Meffert R, Günhan M, Günhan Ö, Özkaya Ö. A histopathological investigation on the efffects of bisphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 2000;71:790-796.
38. Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 1998;63:325-330.
39. Felix R, Bettex JD, Fleish H. Effects of diphosphonates on the synthesis of prostoglandins in cultured calvaria cells. Calcif Tissue Int 1981;33:549-552.
40. Teronen O, Konttinen YT, Lindquisit C, et al. Inhibition of matrix metalloproteinase-1 by dicholoromethylene bisphosphonate (clondronate). Calcif Tissue Int 1997;61: 59-61.
41. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999;878:453-465.
42. Nakaya H, Osawa G, Iwasaki N, Cochman DI, Kamoi K, Oates W. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol 2000;71:1158-1166.
43. Sahni M, Guenther HL, Fleish H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-2011.
44. Shoji K, Horiuchi H, Shinoda HJ. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res 1995;1995:277-284.
45. Flanagon AM, Chambers TJ. Dicholoromethylene bisphosphonate (C12 MBP) inhibits bone resorption through injury to osteoclasts that resorb CL2MBP-coated bone. Bone Miner 1989;6:33-43.
46. Boonecamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986;1:27-39.
47. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
48. Rowe DJ, Hausmann E. The alteration of osteoclast morphology by diphosphonates in bone organ culture. Calcif Tissue Res 1976;20:53-60.
49. Yaffe A, Golomb G, Breuer E, Binderman I. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in rats. J Periodontol 1995;66: 999-1003.
50. Yaffe A, Golomb G, Breuer E, Binderman I. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J Periodontol 2000;71:1607-1612.
51. Binderman I, Adult M, Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 2000;71: 1236-1240.
52. Weinreb M, Quartuccio H, Seedor JG, et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodont Res 1994;29:35-40.
53. Reddy MS, Weatherford TW, Smith CA, et al. Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol 1995;66:211-217.
54. Meraw SJ, Reeve CM. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol 1999;70: 1228-1233.